# Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer

> **NCT00804830** · PHASE2 · TERMINATED · sponsor: **Region Skane** · enrollment: 15 (actual)

## Conditions studied

- Thyroid Neoplasms
- Carcinoma
- Thyroid Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00804830
- **Lead sponsor:** Region Skane
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2012-12
- **Final completion:** 2014-12
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** lack of response
- **Last updated:** 2018-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00804830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00804830, "Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00804830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*